Creo Medical wins 2015 Best for Innovation Award for first new electrosurgery system in a generation
Creo Medical are recognised by the BVCA (British Private Equity & Venture Capital Association) for the development of an innovative electrosurgical platform with wide reaching potential surgical applications
Creo Medical, based in Chepstow, South Wales, an emerging leader in the electrosurgery market, today announced that it has won the Best for Innovation award in the BVCA Management Team Awards for 2015 for the Welsh Regional Awards in Best for Innovation.
Designed in collaboration with the world class Gastroenterology team at St Mark’s Hospital, London, the CROMA platform along with the Speedboat RS2 device has been described as “the first new electrosurgical system in a generation”. Providing a unique combination of bipolar radiofrequency for precise cutting and microwave for controlled coagulation the technology is designed to deliver quicker, safer and more effective results.
Further product developments will focus on providing clinical solutions to complex gastrointestinal problems whilst the platform has further potential in a wide range of other surgical procedures.
Congratulating Creo Medical on winning this award Dr Richard Thompson from Finance Wales’ technology venture investments team said: “The CROMA electrosurgical platform is innovative and ground-breaking. It has a wealth of surgical applications, making it a deserving winner of this prestigious award. Creo’s committed management team led by Craig Gulliford is focused on maximising the company’s future potential. Finance Wales is a long-term backer and we’re pleased to see Creo going from strength to strength since locating its headquarters in Wales. We congratulate them on this latest success and wish them well in the national awards.”
Over 150 UK companies were nominated for the 2015 BVCA Management Team Awards in seven categories. Nominations were subject to rigorous due diligence and in-depth interviews by a judging panel of leading industry figures.
Craig Gulliford, CEO of Creo Medical said: “we are delighted to receive this recognition from the BVCA, in such good company with the other nominees & award winners. We believe that the CROMA electrosurgery platform and Speedboat RS2 device, with it’s unique combination of bipolar RF and microwave energy represents the next steps in the management of certain gastrointestinal lesions, with potential applications extending into many other therapeutic areas. The award recognizes the success of our industry leading team in driving innovation and developing technology designed to improve clinical outcomes for patients worldwide”
The BVCA, including Creo Medical investors Finance Wales, is the industry body for private equity and venture capital in the UK, embracing over 230 private equity and venture capital houses reinforcing the crucial role the industry plays in the global economy as a catalyst for change and growth.